Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine trial results: a watershed moment says immunology expert

The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis has shown. The developers – Pfizer and BioNTech – described it as a “great day for science and humanity”. The analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Daniel Davis,… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Pfizer and BioNTech vaccine COVID-19 candidate found to be more than 90% effective

Pfizer and BioNTech have announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Analysis shows difference of up to three months in current COVID-19 vaccine trial recruitment

Analysis from virtual clinical development specialist Phesi shows the enrolment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrolment, however, looking deeper, there is a significant difference in the Site Effectiveness Index… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna agreement to supply Qatar with mRNA COVID-19 vaccine

Moderna has announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19. “We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date,” said Stéphane Bancel, Moderna’s Chief… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Oxford COVID-19 vaccine follows genetic instructions, analysis finds

The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) has been shown to work as planned. A team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team. This novel analysis… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Global clinical trials of COVID-19 vaccine resume

The Food and Drug Administration (FDA) has today authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford coronavirus vaccine in the USA following the trials restarting in the UK, Brazil, South Africa and Japan. On 6 September, a standard review process triggered a voluntary pause to vaccination across… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

UK government signs deal to help speed up COVID-19 vaccine

hVIVO, has signed a contract with the UK government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus. The contract starts immediately and could be worth approximately £10 million to hVIVO –… Read More

#Covid-19 #News

#Cold chain #Covid-19 #Immunology / Virology & Vaccines

Keeping the cold chain unbroken for COVID research and vaccine development

Robin Vacha, Senior Vice President, Products at Brooks Life Sciences and David Lewandowski, Global Business Development Manager, Cryo Division at Brooks Life Sciences examine the role of unbroken cold chain in research and development As COVID-19 vaccine research continues to grow at an unparalleled pace, so does the need for… Read More

#Covid-19 #Exclusive Content

#Covid-19 #Immunology / Virology & Vaccines

Survey finds three in ten Americans unwilling to have COVID vaccine

Almost seven in 10 Americans would be interested in receiving a COVID-19 vaccine, a study finds. But researchers say there are concerning gaps in interest, particularly among Black Americans, who suffer disproportionately from the virus. Researchers from The Ohio State University surveyed more than 2,000 Americans, asking them about their… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Social distancing shows us we’re better together

What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both… Read More

#Opinion

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Race To COVID-19 cure – the Core Model for solving the pandemic crisis (Part 1 & 2)

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Chemistry #Clinical specialities #Clinical trials #Genetics / genomes #High Content Screening #Immunology / Virology & Vaccines #Pathology #Preclinical #Stem cells #Target validation #Therapeutics

The COVID-19 race: how mouse models will help researchers cross the finish line

THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology / Virology & Vaccines #Molecular medicine #Precision medicine #Preclinical #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

New manufacturing technologies make the promise of stem cell therapies a reality

By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More

#Business & Investment #Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cell therapy #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Honing in on perfect targeting

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More

#Covid-19 #Exclusive Content